(IN BRIEF) SCHOTT Pharma delivered a resilient performance during the first half of fiscal year 2026, reporting revenue growth despite ongoing market challenges and maintaining strong profitability. The company benefited from continued demand for high-value pharmaceutical containment products, especially sterile … Read the full press release
Posted in Business, Financial, Germany, Healthcare, Industrial, Investment, Management, Pharma & Biotech, Science, Technology
Tagged biologics, cartriQ BioPure, Christian Mias, drug containment solutions, drug delivery systems, EBITDA, Frankfurt Stock Exchange, Free cash flow, Germany, GLP-1 therapies, Healthcare Innovation, high-value solutions, Hungary, HVS, injectable drugs, Mainz, mRNA Vaccines, pharmaceutical manufacturing, pharmaceutical packaging, polymer syringes, prefillable glass syringes, Reinhard Mayer, SCHOTT Pharma, SCHOTT Pharma Confirms 2026 Outlook Following Resilient First-Half Results and Expansion Investments, SCHOTT Pharma Maintains Stable Growth and Doubles Free Cash Flow in First Half of Fiscal 2026, SCHOTT Pharma Strengthens Financial Position as Demand for High-Value Drug Solutions Continues to Rise, SDAX, specialty vials, sterile cartridges, Switzerland
(IN BRIEF) The European Investment Bank and European Commission are jointly supporting BioNTech’s mRNA manufacturing facility in Kigali, Rwanda, with up to €95 million in blended financing. The project aims to strengthen Africa’s capacity to produce vaccines locally for diseases … Read the full press release
Posted in Banks, European Union, Financial, Healthcare, Investment, Luxembourg, News, Pharma & Biotech, Technology
Tagged Africa CDC, African Union, and CEPI Join Forces to Strengthen Africa’s Vaccine Independence Through BioNTech’s Kigali mRNA Facility, BioNTech, BioNTech Secures up to €95 Million in EU and EIB Financing to Boost Vaccine Manufacturing Capacity in Kigali, biotechnology, CEPI, Dr Amadou Sall, EIB, EU, European Commission, European Investment Bank, Global Gateway, HIV, Jozef Sikela, Karl Nehammer, Kigali, local production, malaria, mpox, mRNA Vaccines, public health, Rwanda, Sierk Poetting, Sustainable Healthcare, Team Europe, tuberculosis, Vaccine Innovation, vaccine manufacturing
Europe’s RNA immunotherapy sector is gaining speed with new in vivo CAR-T and mRNA vaccine trials. Germany approved the region’s first in vivo CAR-T study, marking regulatory progress. The UK’s Cancer Vaccine Launch Pad advances personalised mRNA cancer vaccine trials … Read the full press release
Posted in Belgium, Business, Germany, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AstraZeneca, ATMP, autoimmunity, BioNTech, BioNTech’s BNT116, biotechnology, Cancer Vaccine Launch Pad, CAR-T therapy, clinical trials, CREATE Medicines, CureVac, EMA, EU-FAB, Europe, Europe Becomes a Hub for Next-Generation RNA Immunotherapy with Strong Clinical and Industrial Momentum, Europe’s Biotech Sector Accelerates RNA-Based Immunotherapy with Breakthroughs in CAR-T and mRNA Vaccines, Europe’s RNA Immunotherapy Industry Poised for Expansion as BioNTech AstraZeneca and CREATE Medicines Lead Advances, Europe’s RNA Immunotherapy Landscape Expands with First In Vivo CAR-T Trial and Growing mRNA Vaccine Efforts, Europe’s RNA Immunotherapy Pipeline Gains Scale as Regulators and Industry Push for Next-Gen Cancer Treatments, fibrosis, Germany, Imfinzi, immuno-oncology, in vivo CAR-T, INT2104, mRNA Vaccines, multi-lineage immune programming, Myeloid Therapeutics, NHS England, oncology, pharma, RNA immunotherapy, RNA Immunotherapy in Europe: Emerging Trials Strategic Mergers and a Clearer Regulatory Path, RNA Immunotherapy Takes Hold in Europe as BioNTech-CureVac Deal and CREATE Medicines Expansion Signal Maturity, RNA therapeutics, RNA-based therapies, United Kingdom
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?